The action mechanism of matrix metalloproteinases-2 （MMP-2） and tissue inhibitor of metalloproteinases-2 （TIMP-2） in the genesis, development and degeneration of haemangioma was investigated by detecting their exp...The action mechanism of matrix metalloproteinases-2 （MMP-2） and tissue inhibitor of metalloproteinases-2 （TIMP-2） in the genesis, development and degeneration of haemangioma was investigated by detecting their expression in the tissue of haemangioma in different phases by using the immunohistochemistry. Fifty paraffin-embedded specimens of skin capillary haemangioma were collected, which were documented in the Department of Pathology, Renmin Hospital of Wuhan University from 2000 to 2006. All samples were stained by regular HE method, and proliferative cell nuclear antigen （PCNA） was tested by immunohistochemical S-P method. The samples were classified according to the Mulliken criteria and the expression pattern of PCNA. Immunohistochemical S-P method was ap- plied to detect the expression of MMP-2 and TIMP-2 in proliferative and degenerative phases of cutaneous capillary haemangioma, and in normal skin tissues. In combination with the detection of the expression of factor Ⅷ-related antigen, it was verified that in haemangioma tissues, the cells expressing MMP-2 and TIMP-2 were vascular endothelial cells. The MMP-2 and TIMP-2 expression was quantitatively analyzed by image analysis system （HPIAS-1000）, and one-way ANOVA（107） and SNK（q） test were done to analyze average absorbance （A） and positive area rate of immunohistochemically positive particles by using SPSS11.5. The results showed： （1） Among 50 samples of haemangioma, there were 26 proliferative haemangiomas, and 24 degenerative haemangiomas, respectively; （2） The expression of MMP-2 was weak in normal vascular endothelial cells, cytoplasm of connective tissues and extracellular matrix around blood vessels. The expression of MMP-2 in proliferative group was significantly higher than in degenerative group and control group （normal skin） （P〈0.05）, but there was no statistically significant difference between the latter two groups; （3） TIMP-2 was highly expressed in normal tissues, degenerative vascular en展开更多
目的探讨基质金属蛋白酶-2(matrix metalloproteinases-2,MMP-2)/基质金属蛋白酶组织抑制剂-2(tissueinhibitor of matrix metalloproteinases-2,TIMP-2)与2型糖尿病大鼠心肌间质中胶原代谢的关系,及瑞舒伐他汀防治心肌间质纤维化的可...目的探讨基质金属蛋白酶-2(matrix metalloproteinases-2,MMP-2)/基质金属蛋白酶组织抑制剂-2(tissueinhibitor of matrix metalloproteinases-2,TIMP-2)与2型糖尿病大鼠心肌间质中胶原代谢的关系,及瑞舒伐他汀防治心肌间质纤维化的可能机制。方法30只雄性SD大鼠按随机数字表法抽取8只作为正常对照组,其余22只喂高脂,高糖饲料,并予低剂量链脲佐菌素单次腹腔注射。16只成模的糖尿病组大鼠按随机数字表法分成糖尿病组(n=8)与瑞舒伐他汀治疗组(n=8)。待血糖稳定后,治疗组开始给予瑞舒伐他汀干预处理,干预两个月后,处死大鼠,测定动物体质量,心脏质量,以计算心脏质量指数:心脏质量(g)/动物体质量(g)。酶联免疫吸附试验(ELISA)法分别测定3组大鼠血浆MMP-2、TIMP-2浓度,采用免疫组化方法检测心肌MMP-2、TIMP-2蛋白表达的水平和组织定位,采用Masson染色方法观察心肌间质胶原蛋白含量变化及分布。结果糖尿病组及治疗组血糖高于正常组,差异有统计学意义(P<0.05)。糖尿病组心脏质量指数高于治疗组和正常组,差异有统计学意义(P<0.05)。糖尿病组血浆MMP-2及TIMP-2浓度均比正常组高,差异有统计学意义(P<0.05)。治疗组血浆MMP-2及TIMP-2浓度比糖尿病组降低,差异有统计学意义(P<0.05)。然而,免疫组化检测到MMP-2在糖尿病组心肌间质中表达比正常组明显减少,在治疗组的表达比在糖尿病组增多,差异有统计学意义(P<0.05);TIMP-2在糖尿病组心肌间质中表达比正常组明显增多,在治疗组的表达比在糖尿病组减少,差异有统计学意义(P<0.05)。糖尿病组与正常组比较,MMP-2/TIMP-2比值下降;治疗组与糖尿病组比较,MMP-2/TIMP-2比值上升。心肌Masson染色:亮绿色纤维在糖尿病组心肌间质中明显比正常组增多,而治疗组比糖尿病组有所减少。结论糖尿病大鼠中MMP-2/TIMP-2比值下降可能是导致心肌间质纤维化的原因之一。瑞舒�展开更多
Background Excessive deposition of extraceUular matrix （ECM） in the kidney is the hallmark of diabetic nephropathy. Increased matrix synthesis has been well documented but the effects of diabetes on degradative path...Background Excessive deposition of extraceUular matrix （ECM） in the kidney is the hallmark of diabetic nephropathy. Increased matrix synthesis has been well documented but the effects of diabetes on degradative pathways, particularly in the in vivo setting. The renal protective effect of these pathways on matrix accumulation has not been fully elucidated. The present study was understaken to investigate the activity of matrix metalloproteinase-2 （MMP-2）, the expression of MMP-2 and tissue inhibitor of metalloproteinase-2 （TIMP-2） in kidney tissues of diabetic rats, and to explore the degradative pathway of type Ⅳ collagen （Ⅳ-C） and the renal protective effects of ACE inhibition- benazepril.展开更多
Background The cholesterol-lowering statin drugs have some non-lipid-lowering effects, such as inhibiting myocardial remodeling. However, the underlying mechanism is still unclear. Methods The left anterior descending...Background The cholesterol-lowering statin drugs have some non-lipid-lowering effects, such as inhibiting myocardial remodeling. However, the underlying mechanism is still unclear. Methods The left anterior descending coronary artery was ligated to establish a rat model of heart failure, and the rats were divided into a sham operation （SO） group, myocardial infarction model （MI） group, and MI-atorvastatin group. Changes in hemodynamic parameters were recorded after the final drug administration. Histological diagnosis was made by reviewing hematoxylin and eosin （HE） stained tissue. Real-time quantitative polymerase chain reaction （PCR） was performed to determine the expressions of type I and type III collagen, matrix metalloproteinase-2 （MMP-2）, and tissue matrix metalloproteinase inhibitor-2 （TIMP-2）. Further, primary rat cardiac fibroblasts were cultured and the MTT assay was performed to determine the effect of atorvastatin on cardiac fibroblast proliferation. Results The model of heart failure was established and the results of HE staining and Masson＇s trichrome staining revealed that the rats in the heart failure group showed obvious hyperplasia of fibrotic tissue, which was significantly reduced in the atorvastatin group. Real-time quantitative PCR showed that the MI group showed a significantly increased expression of type I and type III coltagen, MMP-2, and TIMP-2, but a significantly reduced MMP-2/T＇IMP- 2 ratio. Compared with the MI group, the atorvastatin group showed significantly reduced expression of type I and III collagen, unchanged expression of MMP-2, significantly reduced expression of TIMP-2, and an increased MMP-2/ TIMP-2 ratio. We further found that atorvastatin significantly inhibited the Ang II-induced fibroblast proliferation and the expression of type I and type III collagen in cardiac fibroblasts while increasing the MMP-2/TIMP-2 ratio. Conclusions These data suggest that atorvastatin can inhibit cardiac fibroblast proliferation and enhance collagen degradati展开更多
基金supported by a grant from the National Natural Sciences Foundation of China (No.30872688)
文摘The action mechanism of matrix metalloproteinases-2 （MMP-2） and tissue inhibitor of metalloproteinases-2 （TIMP-2） in the genesis, development and degeneration of haemangioma was investigated by detecting their expression in the tissue of haemangioma in different phases by using the immunohistochemistry. Fifty paraffin-embedded specimens of skin capillary haemangioma were collected, which were documented in the Department of Pathology, Renmin Hospital of Wuhan University from 2000 to 2006. All samples were stained by regular HE method, and proliferative cell nuclear antigen （PCNA） was tested by immunohistochemical S-P method. The samples were classified according to the Mulliken criteria and the expression pattern of PCNA. Immunohistochemical S-P method was ap- plied to detect the expression of MMP-2 and TIMP-2 in proliferative and degenerative phases of cutaneous capillary haemangioma, and in normal skin tissues. In combination with the detection of the expression of factor Ⅷ-related antigen, it was verified that in haemangioma tissues, the cells expressing MMP-2 and TIMP-2 were vascular endothelial cells. The MMP-2 and TIMP-2 expression was quantitatively analyzed by image analysis system （HPIAS-1000）, and one-way ANOVA（107） and SNK（q） test were done to analyze average absorbance （A） and positive area rate of immunohistochemically positive particles by using SPSS11.5. The results showed： （1） Among 50 samples of haemangioma, there were 26 proliferative haemangiomas, and 24 degenerative haemangiomas, respectively; （2） The expression of MMP-2 was weak in normal vascular endothelial cells, cytoplasm of connective tissues and extracellular matrix around blood vessels. The expression of MMP-2 in proliferative group was significantly higher than in degenerative group and control group （normal skin） （P〈0.05）, but there was no statistically significant difference between the latter two groups; （3） TIMP-2 was highly expressed in normal tissues, degenerative vascular en
文摘目的探讨基质金属蛋白酶-2(matrix metalloproteinases-2,MMP-2)/基质金属蛋白酶组织抑制剂-2(tissueinhibitor of matrix metalloproteinases-2,TIMP-2)与2型糖尿病大鼠心肌间质中胶原代谢的关系,及瑞舒伐他汀防治心肌间质纤维化的可能机制。方法30只雄性SD大鼠按随机数字表法抽取8只作为正常对照组,其余22只喂高脂,高糖饲料,并予低剂量链脲佐菌素单次腹腔注射。16只成模的糖尿病组大鼠按随机数字表法分成糖尿病组(n=8)与瑞舒伐他汀治疗组(n=8)。待血糖稳定后,治疗组开始给予瑞舒伐他汀干预处理,干预两个月后,处死大鼠,测定动物体质量,心脏质量,以计算心脏质量指数:心脏质量(g)/动物体质量(g)。酶联免疫吸附试验(ELISA)法分别测定3组大鼠血浆MMP-2、TIMP-2浓度,采用免疫组化方法检测心肌MMP-2、TIMP-2蛋白表达的水平和组织定位,采用Masson染色方法观察心肌间质胶原蛋白含量变化及分布。结果糖尿病组及治疗组血糖高于正常组,差异有统计学意义(P<0.05)。糖尿病组心脏质量指数高于治疗组和正常组,差异有统计学意义(P<0.05)。糖尿病组血浆MMP-2及TIMP-2浓度均比正常组高,差异有统计学意义(P<0.05)。治疗组血浆MMP-2及TIMP-2浓度比糖尿病组降低,差异有统计学意义(P<0.05)。然而,免疫组化检测到MMP-2在糖尿病组心肌间质中表达比正常组明显减少,在治疗组的表达比在糖尿病组增多,差异有统计学意义(P<0.05);TIMP-2在糖尿病组心肌间质中表达比正常组明显增多,在治疗组的表达比在糖尿病组减少,差异有统计学意义(P<0.05)。糖尿病组与正常组比较,MMP-2/TIMP-2比值下降;治疗组与糖尿病组比较,MMP-2/TIMP-2比值上升。心肌Masson染色:亮绿色纤维在糖尿病组心肌间质中明显比正常组增多,而治疗组比糖尿病组有所减少。结论糖尿病大鼠中MMP-2/TIMP-2比值下降可能是导致心肌间质纤维化的原因之一。瑞舒�
基金This study was supported by a grant from the Natural Science Foundation of Shandong Province (No. Y2002C35).
文摘Background Excessive deposition of extraceUular matrix （ECM） in the kidney is the hallmark of diabetic nephropathy. Increased matrix synthesis has been well documented but the effects of diabetes on degradative pathways, particularly in the in vivo setting. The renal protective effect of these pathways on matrix accumulation has not been fully elucidated. The present study was understaken to investigate the activity of matrix metalloproteinase-2 （MMP-2）, the expression of MMP-2 and tissue inhibitor of metalloproteinase-2 （TIMP-2） in kidney tissues of diabetic rats, and to explore the degradative pathway of type Ⅳ collagen （Ⅳ-C） and the renal protective effects of ACE inhibition- benazepril.
文摘Background The cholesterol-lowering statin drugs have some non-lipid-lowering effects, such as inhibiting myocardial remodeling. However, the underlying mechanism is still unclear. Methods The left anterior descending coronary artery was ligated to establish a rat model of heart failure, and the rats were divided into a sham operation （SO） group, myocardial infarction model （MI） group, and MI-atorvastatin group. Changes in hemodynamic parameters were recorded after the final drug administration. Histological diagnosis was made by reviewing hematoxylin and eosin （HE） stained tissue. Real-time quantitative polymerase chain reaction （PCR） was performed to determine the expressions of type I and type III collagen, matrix metalloproteinase-2 （MMP-2）, and tissue matrix metalloproteinase inhibitor-2 （TIMP-2）. Further, primary rat cardiac fibroblasts were cultured and the MTT assay was performed to determine the effect of atorvastatin on cardiac fibroblast proliferation. Results The model of heart failure was established and the results of HE staining and Masson＇s trichrome staining revealed that the rats in the heart failure group showed obvious hyperplasia of fibrotic tissue, which was significantly reduced in the atorvastatin group. Real-time quantitative PCR showed that the MI group showed a significantly increased expression of type I and type III coltagen, MMP-2, and TIMP-2, but a significantly reduced MMP-2/T＇IMP- 2 ratio. Compared with the MI group, the atorvastatin group showed significantly reduced expression of type I and III collagen, unchanged expression of MMP-2, significantly reduced expression of TIMP-2, and an increased MMP-2/ TIMP-2 ratio. We further found that atorvastatin significantly inhibited the Ang II-induced fibroblast proliferation and the expression of type I and type III collagen in cardiac fibroblasts while increasing the MMP-2/TIMP-2 ratio. Conclusions These data suggest that atorvastatin can inhibit cardiac fibroblast proliferation and enhance collagen degradati
